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Purpose. To conduct clinical and genetic studies in a European 
family with autosomal dominant Stargardt-like macular dystro­
phy (adSTGl>like Ml)) and to investigate the functional conse­
quences of a novel FLOV1.4 mutation.
Methods. Ophthalmic examination and mutation screening by 
direct sequencing of the FLOV1.4 gene was perform ed in two 
affected individuals. Wild-type and mutant FLOV1.4 genes were 
expressed as enhanced green fluorescent protein (KGFP) fu­
sion proteins in transient transfection in N1H-3T3 and HHK293 
cells. To determine the subcellular localization of BLOVL4, an 
endoplasmic-reticulum (HR)-specific marker for pl)sRed2-BR 
was cotransfected with BLOVL4 constructs. Transfected cells 
w ere viewed by confocal microscopy. Western blot analysis 
was perform ed to assess protein expression using an anti-GFP 
antibody.
Reslxts. Affected patients exhibited macular atrophy with sur­
rounding flecks characteristic of adSTGl)-like Ml). A novel 
FLOV1.4 p.Tyr270X mutation was detected in affected individ­
uals. In cell-transfection studies, wild-type BLOVL4 localized 
preferentially to the BR. In contrast, the mutant protein ap­
peared to be mislocalized within transfected cells. 
Conclusions. In a Buropean family with adSTGl)-like Ml), a 
novel FLOV1.4 mutation was found to underlie the disorder. 
Transfection studies indicated that, unlike wild-type BLOVL4, 
the mutant protein does not localize to  the BR but rather 
appears to be sequestered elsewhere in an aggregated pattern
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in the cytoplasm. Further analysis of the function of normal and 
mutant BLOVL4 will provide insight into the mechanism of 
macular degeneration. (In ve s t O ph tha lm ol Vis Sci. 2004;45: 
4263-4267) 1)01:10.1 167/iovs.04-0078
O  targardt disease (STG1)) is an early-onset hereditary macular 
O  dystrophy, characterized by decreased central vision, atro­
phy of the macula, and frequent appearance of orange-yellow 
flecks in the posterior pole of the retina.1 STG1) is most com­
monly inherited as an autosomal recessive trait, but numerous 
affected families have been described in which features of the 
disease showed autosomal dominant (ad) i n h e r i t a n c e . M u ­
tations in the photoreceptor-specific ABCA4  gene seem to 
account for all recessive forms of STG1) (STG1) 1; M1M248200). 
Conversely, adSTGl) is a genetically heterogeneous disorder, as 
two loci already have been identified. One locus for adSTGl) 
was mapped to 4p (STC.1)4; M1M603786).' Another locus 
(STG1)3, M1M600110) was localized to 6ql 4 in a large North 
American family.2 Subsequently, several additional adSTGl)- 
like families and ad macular dystrophy (adMl)) families were 
mapped to the STG1)3 locus.5’6’91” Genealogy7 and haplotype 
analyses indicated that they w ere all linked through an ances­
tral founder.5’71” Positional cloning revealed that a photore­
ceptor-specific gene, FLOV1.4 (elongation of very long chain 
fatty acids-like 4) is responsible for STG1)3.7 The BLOVL4 
protein was shown to be homologous to a group of yeast 
proteins involved in the biosynthesis of very-long-chain fatty 
acids and is likely to play a central role in the biosynthesis of 
lipid com ponents of the photoreceptor outer segment mem­
brane. A 5-bp deletion in the FLOV1.4 gene was found to 
segregate with the disease in all five families.7 Subsequently, 
the identification of a second mutation in the FLOV1.4 gene in 
a large unrelated pedigree confirmed FLOV1.4 as a disease- 
causing gene in adMl) and adSTGl).s The second mutation 
consisted of two 1-bp deletions separated by four nucleotides, 
w hich occurred at the same location as the previously de­
scribed 5-bp deletion and had an almost identical predicted 
truncating effect on the BLOVL4 protein.
Herein, w e describe the identification of a third FLOV1.4 
mutation in a Buropean family with adSTGl)-like macular dys­
trophy. To assess the functional consequence of this FLOV1.4 
mutation, w e investigated the subcellular location of normal 
and mutant BLOVL4. We demonstrated that the wild-type en­
hanced green fluorescent protein (BGFP>BLOVL4 fusion pro­
tein localizes to the BR compartment in transfected cells. In 
contrast, the mutant BGFP-BLOVL4 fusion protein does not 
localize to the BR but rather appears to be sequestered else­
w here in an aggregate pattern in the cytoplasm.
M ethods 
Patients
Two individuals with adSTGD-like MD, a woman in a Belgian family 
and her affected daughter, were available for clinical and molecular 
investigation (patients ITT:2 and TV:1, Fig. 1). Both patients gave their
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MO). Chamber slides were purchased from Nalge Nunc (Roches­
ter. NY).
G e n e ra tio n  o f  E x p re s s io n  C o n s tru c ts . Wild-type and mu­
tant F.l.OVlA cDNAs were cloned separately into a pF.GFPCl vector 
(RD-Clontech. Palo Alto. CA). This vector utilizes a cytomegalovirus 
(CMV) promoter and expresses F.GFP after transfection into mamma­
lian cells. PCR was performed with one forward primer containing a 
KpnJ site (5'-CGGGGTACCGCGATGGGGCTCCTGGACTC-3'). and two 
reverse primers containing a Bam  HI site (5'-CGGGATCCCGTTAATC- 
TCCTTTTGCTTTTC-3' for the wild-type FI.OV1.4 and 5'-CGGGATC- 
CCGCTATGTCCGAATGTAGAAG-3' for the mutant 270X F.l.OVlA). 
with wild-type cDNAs used as a template. The resultant PCR products 
were digested with Kpn\ and BcmiHl. and cloned into the KpnJ and 
BcimHl sites of a pF.GFPCl vector in frame at the C-terminal end of 
F.GFP. The recombinant plasmids containing F.GFP-ET.OVT/i fusion con­
structs were verified by direct DNA sequencing, amplified and purified 
with a plasmid isolation kit (Qiagen. Tnc.. Valencia. CA).
C ell T ra n s fe c tio n  a n d  Im a g in g . NTH3T3 and HF.K293 were 
used for all transfection studies. The recombinant plasmids were trans­
fected into the cell lines using T.ipofectamine Reagent 2000 (Tnvitro- 
gen-Gibco) according to the manufacturer's protocol. Cells were mon­
itored for fluorescence between 7 and 36 hours after transfection, by 
epifluorescence microscopy.
NTH3T3 cells were seeded onto poly-i.-lysine-coated, four-well 
chamber glass slides at a confluence of 20% to 30% and transfected 
with recombinant plasmids containing wild-type or mutant F.l.OVlA. 
Cotransfection with an ER-organelle-specific marker pDsRed2F.R was 
performed with wild-type and mutant F.T.OVT/i to determine the sub- 
cellular localization of ET.OVT.4. Transfected cells were incubated at 
37°C for 2 4  hours, washed with PBS. fixed in methanol-acetone (50:50. 
vol/vol). and mounted on glass slides with antifade medium (Vecta- 
shicid; Vector I.aboratories. Tnc.. Burlingame. CA) for microscopy. To 
assess subcellular localization of wild-type and mutant F.T.OVT/i protein, 
transfected cells were observed at different time intervals. However, all 
data were collected at approximately the same time point after trans­
fection.
Tillages of green fluorescence were collected with a confocal laser 
scanning microscope (TX70; Olympus. Tokyo. Japan) using a 488-nm 
excitation source and a 505- to 550-nm band-pass barrier filter. A red 
fluorescence (DsRed2) marker for F.R was examined using 568-nm 
excitation light from the Kn laser, a 575-nm dichromic mirror, and a 
580- to 625-nm filter. The cells were illuminated sequentially to avoid
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T a b le  2 . Clinical Features of the Patients with Autosomal Dominant Stargardt Disease








Cy) OD OS Fundus Characteristics Scotopic Photopic 30 H7.
TTT:2 39 i i 20/400 20/400 Macular pigmentary changes; 
perimacular yellow flecks






TV:1 16 9 20/400 20/400 Macular pigmentary changes; 
progressive increase of 
yellow flecks in the 
posterior pole
Macular RPE window 
defects
Normal Subnormal Normal
F ig u r e  1 . Pedigree of the autosomal dominant STGD family de­
scribed in this study.
informed consent before inclusion in the study as part of a protocol 
that adhered to the tenets of the Declaration of Helsinki. Clinical 
investigation included visual acuity measurement, dilated fundus ex­
aminations. and fluorescein angiography.
Mutation Analysis
DNA of both patients was screened by direct sequence analysis of all 
six exons and flanking splice sites of the F.l.OVlA. gene using primers 
and conditions as reported in Table 1. The identified novel F.l.OVlA. 
mutation was tested on a panel of 96 ethnically matched control 
individuals, using an amplification-refractory mutation specific (ARMS) 
technique.11 Wild-type-allele-specific and mutant-allele-specific for­
ward primers used for ARMS were, respectively. 5'-AACTTCTACAT- 
TCGGACATAC-3' and 5'-AACTTCTACATTCGGACATAG-3'. The re­
verse primer was 5'-TCAACAACAGTTAAGGCCCA-3'.
Transfection Studies
Media and reagents for cell culture and transfection were purchased 
from Tnvitrogen-Gibco (Grand Island. NT). Anti-F.GFP monoclonal an­
tibody and poly-i.-lysine were purchased from Sigma-Aldrich (St. T.ouis.
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Figure 2. Fundus photographs and 
fluorescein angiograms of patients 
IV: 1 (A-C) and TTI:2 (D-G). carrying 
the p.Tyr270X FT.OVT.4 mutation. (A.
B) Patient TV:1 at 10 years of age. (A)
Fundus photograph showing dis­
crete macular alterations but no 
flecks. (B) Fluorescein angiography 
demonstrating window defects in 
the macula. (C) Fundus photograph 
of patient FV:1 at age 16. Yellow 
flecks extend beyond the arcade ves­
sels. (D-G) Patient 111:2 at the age 39.
(D. E) Characteristic yellow flecks in 
the perimacular area. RPF atrophy, 
and pigmentary changes are shown.
(F. G) Fluorescein angiography pho­
tographs of the left eye (F) in a mid­
dle phase and of the right eye (G) in 
the late venous phase, showing early 
fluorescence in the macular area due 
to RPF atrophy.
bleed through (3.7 seconds per frame for FGFP and DsRed2). and 
images were collected in a single optical section of 0.35 ftm, where 
they were compared for colocalization analyses.
E le c t ro p h o re s is  a n d  Im m u n o b lo t  A n a ly sis . To analyze 
the expression of wild-type and mutant FT.OVT.4. we grew transfected 
cells for 24 hours, harvested them from the plates, and briefly washed 
them with PBS. Cells were lysed on ice for 20 minutes with a buffer 
containing 1% Triton X-100. 0.01% SDS. 0.05 M Tris-HCl. and 1 mM
FDTA (pH 7.5). The cell lysates were centrifuged at 4000 rpm for 5 
minutes and the supernatants used for electrophoresis.
SDS-polyacrylamide gel electrophoresis (SDS-PAGF) was performed 
according to the method of I.aemmli.12 Ten microliters of sample (~7 
jug) was loaded onto a 9% polyacrylamide gel and electrophoresed at 
110 V for 1 hour. The resolved proteins were transferred to a polyvi- 
nylidene difluoride (PVDF) membrane (Millipore. Billerica. MA) and 
blocked for 2 hours at room temperature with 5% skim milk in Tris-
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Figure 3. Western blot analysis of ET.OVT.4 expression in NTH3T3 
cells. Transfected cells were allowed to express EGFP-EI.OVI.4 fusion 
proteins (Jane 1: Tyr270stopEI,OVT,4; lane 2: wtFI,OVI,4) and EGFP 
alone (lane J)  for 24 hours, followed by immunoblot analysis with 
anti-GFP monoclonal antibody.
buffered saline containing 0.05% Tween 20 (TTRS). The membrane 
was incubated for 2 hours with monoclonal anti-GFP antibody diluted 
1:2000 in 5% milk containing TTRS. and then probed with peroxidase- 
conjugated anti-mouse antibody (1:4000 dilution in TTRS; Amersham 
Riosciences. Piscataway. NJ) for 1 hour and developed with a chemi- 




Clinical features of both patients included in the study (pa­
tients 111:2 and IV: 1) are summarized in Table 2.
Patients experienced vision loss at young age (11 and 9 
years, respectively). At 26 years of age, the mother (111:2) had 
a visual acuity of 20/400 in both eyes. At 16 years of age, the 
visual acuity of her daughter (IV: 1) also had decreased to 
20/400 in both eyes. In both patients, the fundus examinations 
showed macular pigmentary changes and the appearance of
yellow flecks characteristic of adSTC.D-like MI) (Figs. 2C-H). 
Fluorescein angiography revealed macular RPH defects in both 
individuals (Figs. 215, 2F, 2C,).
ELOVL4 Mutation Analysis
Because mutations in the ELOVL4 gene had been associated 
with adSTC.I), w e screened both patients for mutations in 
ELOVL4. In both patients, we identified a C-to-C. change at 
nucleotide c.810 in exon 6 of the ELOVL4 gene. This change 
resulted in a novel substitution of a stop codon for tyrosine 
270, leading to  a truncated protein lacking the last 45 amino 
acids. The mutation was not found in 96 healthy control indi­
viduals.
Characterization o f  EGFP-ELOVL4 Fusion Proteins
We expressed wild-type and mutant HLOVL4 as F.GFP fusion 
proteins to  facilitate direct visualization of subcellular localiza­
tion. W estern blot analysis confirmed the synthesis of FC.FP- 
FLOVL4 fusion proteins, and single bands w ere visualized for 
each construct at ~ 6 l kl)a for wild-type FLOVL4 and ~ 56  kl)a 
for the HGFP-HLOVL4 truncated mutant (Fig. 3).
Subcellular Localization o f  ELOVL4
Confocal microscopy was used to determine the subcellular 
localization of wild-type and mutant FC.FP-FLOVL4 in trans­
fected NIH3T3 cells. Wild-type HGFP-HLOVL4 localized prefer­
entially to  the endoplasmic reticulum (FR) compartment (Fig. 
4). In contrast, mutant FC.FP-FLOVL4 showed a markedly dif­
ferent subcellular localization pattern in the transfected cells. It 
did not localize to the FR. Instead, the pattern of its subcellular 
distribution is consistent w ith an aggregated form in the cyto­
plasm (Fig. 4). As a control, FC.FP when expressed alone, 
localized to  the cytoplasm (data not shown).15
D iscussion
Autosomal dominant STC.D-like MI) is a juvenile macular dys­
trophy. Most affected families in North America have been 
linked to  the STC.D3 locus on 6 q l4 .2-5f' y l° Subsequently, 
haplotype and ELOVL4 mutation analyses have shown that all 
affected individuals share the same disease haplotype5’71” and 
harbor a 5-bp deletion in the ELOVL4 gene.7 The only unre­
lated family described up to  now was also of North American 
origin and carried a 2-bp deletion mutation that, oddly enough, 
occurred at the same location as the previously described 5-bp 
deletion.51
Herein, w e describe the identification of a novel ELOVL4 
mutation in a family of European origin w ith adSTC.D-like MI). 
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Figure 4. Localization of FI.OVT.4 
with FR-organelle-specific markers 
in NTH3T3 cells. Twenty-four hours 
after cotransfection. the cells were 
imaged by confocal microscopy. (A) 
Cotransfected cell with FGFP-wtF- 
I.OVI.4 and pDsRed2-FR. specific for 
endoplasmic reticulum. (B) Cotrans­
fected cell with FGFP-mtFI,OVI,4 and 
pDsRed2-FR. Green: expression of 
FI.OVT.4; reel. FR organelle. Merged 
image: superimposed image of ex­
pression of FI.OVT.4 and the FR 
organelle.
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Both previously identified EI.OVI.4 mutations were small 
deletions that generate a frameshift leading to a truncated 
protein lacking the last 51 amino acids.7,s The p.Tyr270X 
mutation results in the absence of the last 45 amino acids. In all 
three cases, a KXKXX dilysine-targeting signal at the carboxyl 
terminus of the KLOVL4 protein is deleted. This signal is 
known to be responsible for the retention of transmembrane 
proteins in the KR,1J the site of very-long-chain fatty acid 
biosynthesis.15 As expected, subcellular localization studies 
showed that, unlike wild-ty'pe KLOVL4, the mutant does not 
localize to the HR. The mislocalized protein seems to be se­
questered in another subcellular com partment exhibiting 
dense fluorescence-positive aggregates. Similar results were 
also observed with 5-bp KLOVL4 mutants.16,17 Future studies 
with additional cell markers and/or electron microscopy will 
elucidate the subcompartmental localization and underlying 
mechanism of the KLOVL4 mutant proteins.
It is interesting that all three El.OVl.4 mutations were clus­
tered in the C terminus; so far, no mutations in the N terminus 
have been reported. This may suggest a dominant negative 
nature of the mutant KLOVL4 protein, rather than a mechanism 
of haploinsufficiency. Consistent w ith this notion, the 5-bp 
deletion mutant causes cell death when transfected into cul­
tured cells.17
The identification of the third mutation in the ELOVL4 gene 
further supports its important role in macular degeneration, 
and provides another entry point from which KLOVL4 function 
in retinal physiology7 and disease can be investigated.
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